RUNX1 and acute myeloid leukemia: P1 program was not associated with risk groups, but it was significantly depleted from samples with RUNX1::RUNX1T1 fusion (Fig. 2B), which is associated with worse prognosis in pediatric AML compared to patients without this mutation [31].